Ot­su­ka and Lund­beck get FDA nod for schiz­o­phre­nia, bipo­lar dis­or­der in­jec­tion

The FDA ap­proved a new long-act­ing drug for schiz­o­phre­nia and bipo­lar dis­or­der on Thurs­day, adding to the grow­ing rank of drugs for the men­tal dis­or­ders that don’t have to be tak­en as an oral dai­ly treat­ment.

Ot­su­ka and Lund­beck’s Abil­i­fy Asimtu­fii (arip­ipra­zole) on­ly needs to be in­ject­ed once every two months. The FDA ap­proved their NDA for the ex­tend­ed-re­lease in­jectable as a treat­ment for schiz­o­phre­nia and a main­te­nance ther­a­py for adults with bipo­lar I.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.